Condition: Relapsed or Refractory B-cell Malignancies · Follicular Lymphoma (FL) · Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
This description comes directly from the study's public registry record.
Exscientia AI Ltd. · 385-374-1724 · clinicaltrials@recursion.com
Always discuss trial participation with your own doctor first.
| LLC ARENSIA Exploratory Medicine | Tbilisi, Georgia | Recruiting |
| IMSP Institute of Oncology, ARENSIA Exploratory Medicine | Chisinau, Moldova | Recruiting |
| Hospital Beata Maria Ana | Madrid, Spain | Recruiting |
| Hospital Fundación Jiménez Diaz | Madrid, Spain | Recruiting |
| Hospital Universitario HM Sanchinarro | Madrid, Spain | Recruiting |
| Clinica Universidad de Navarra | Pamplona, Spain | Recruiting |
| Medical Center of LLC ARENSIA Exploratory Medicine | Kyiv, Ukraine | Recruiting |
| St James's University Hospital | Leeds, United Kingdom | Recruiting |
| University Hospitals Plymouth NHS Trust (Derriford Hospital) | Plymouth, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06980116